GILD : Analysis & Opinions

  1. How Gilead Plans to Keep Competitors in Check

    April 14, 2015
    Gilead Sciences (NASDAQ: GILD) has plenty of experience in outmaneuvering competitors. After all, despite competitors' launching ...
  2. Why Merck's Victory Is of Little Concern to Gilead

    April 10, 2015
    Merck (NYSE: MRK) investors can be proud, as the company's persistence appears to be paying off. While Gilead Sciences (NASDAQ: ...
  3. Gilead's Little Tweak Could Produce Big Revenue

    April 8, 2015
    Sometimes it's the little things companies do that can have the biggest impacts on their bottom line. Take Gilead Sciences ...
  4. Top 7 Roth IRA Stocks for 2015

    April 8, 2015
    Looking for stocks with long-term potential for your Roth IRA? Here are the top seven picks for 2015.
  5. Risks and Rewards of Biotech Companies

    April 1, 2015
    We look at the risks and rewards of investing in biotech companies.
  6. 3 Under-the-Radar Risks for Gilead Sciences

    March 27, 2015
    Put mildly, biotechnology company Gilead Sciences (NASDAQ: GILD) is nothing short of a cash flow behemoth. Over the past ...
  7. Read This Before You Sell Gilead Sciences

    March 25, 2015
    Earlier this week, Gilead Sciences (NASDAQ: GILD) reported that nine people who were taking a specific heart disease drug ...
  8. Why These Could Be 2015's 10 Best Biotech Stocks

    March 25, 2015
    A quick look at a 10 biotech companies that are poised to deliver for shareholders in 2015.
  9. Could Gilead's Dividend Have Additional Upside?

    March 23, 2015
    Gilead Sciences (NASDAQ: GILD) could offer a blueprint for a successful biotech company for its peers to emulate. The past ...
  10. Gilead Sciences' Drugs: Worth $136 Billion?

    March 19, 2015
    Doctors and patients are cheering new advances in treating hepatitis C, a common disease that affects millions of people ...
  11. This Policy Shift Is Big News for Gilead Sciences

    March 17, 2015
    GILD data by YCharts. By and large, Gilead Sciences had a banner year in 2014. In December 2013 Gilead witnessed its revolutionary ...
  12. Why Celgene Won't Pay A Dividend Anytime Soon

    March 12, 2015
    The biotech sector has been virtually unstoppable over the past three years and has widely outperformed the broader market. ...
  13. Gilead Sciences: The New Market-Share Leader

    March 2, 2015
    Gilead Sciences's track record of developing and commercializing therapies has turned it into the market-share leader; investros ...
  14. How Gilead Sales Have Grown Conspicuously?

    February 23, 2015
    Learn how Gilead sales have climbed from $1.33 billion in 2004 to $24.89 billion as of the end of 2014.
  15. Day's First Trade Can Serve As Support/Resistance

    January 22, 2015
    The first trade of the day in liquid markets defines a narrow price level that can act as support or resistance for the entire ...
  16. The Biggest Biotech Companies

    January 15, 2015
    These biotech firms want to revolutionize medicine. If successful, they may see high profits, but investing in these companies ...
  17. How Does Janus's Fund Lineup Look Now?

    November 14, 2014
    With the addition of 'Bond King' Bill Gross, Janus is a changed firm. Here's what its fund lineup looks like now.
  18. Big Swings in Biotech Short Interest

    October 13, 2014
  19. Shocking Prediction #9: 'Nightmare Pandemics' Could Make These ...

    August 27, 2014
    Let me start off today's issue with a warning... We're not trying to sound alarmist. It does absolutely zero good ...
  20. 4 Large-Cap Healthcare Stocks To Watch

    August 18, 2014
    Healthcare continues to a be a hot sector. Here are four pharma stocks to keep an eye on for entry points.
  21. How Gilead Sciences Became A Big Name In Biotech

    August 11, 2014
    How does a company start with an unfortunate bout of dengue fever and grow to be a multibillion dollar corporation?
  22. The Most Undervalued Stock In The Biotech Universe

    May 6, 2014
    If you've been paying attention to the biotech and pharmaceutical space over the past few months (like my colleague David ...
  23. Four Reasons I Love Monthly Dividend Payers... And You Should, ...

    May 6, 2014
    Recently, I investigated installing solar panels on my roof to reduce my monthly energy bills. The financial calculations ...
  24. What Are The Best Bets In Biotech?

    May 2, 2014
    The NASDAQ Biotechnology Index is off nearly 20% as its components busy themselves with hostile bids and frenzied buying ...
  25. 7 Picks For A Sector That's Heating Up

    April 29, 2014
    We're right in the middle of earnings season, which means that most mid- and large-cap companies have reported results, with ...
  26. This Sector's Earnings Are Just Heating Up

    April 29, 2014
    We're right in the middle of earnings season, which means that most mid- and large-cap companies have reported results, with ...
  27. Markets Falling? Get Your Defense Ready

    April 14, 2014
    The stock market is getting whacked. The question now for many investors is, what to do about it. The first thing to ...
  28. Stocks Looking to Bounce off Trendline Support

    March 12, 2014
    These stocks are testing trendline support, offering a buying opportunity. If they fall further though, it warns of a correction.
  29. The 3 Best Growth Stocks To Buy On A Pullback

    February 13, 2014
    Nothing feels worse for investors than missing the boat, and I'm sure there's plenty of regret to go around these ...
  30. These Companies Know The Future Before It Happens

    February 13, 2014
    Wouldn't it be great to have a crystal ball to see into the future?You could know when the next market crash will be, ...
  31. Gilead Sciences Leads In Rising Short Interest Among Biotechs

    November 12, 2013
    Among leading biotech and emerging pharmaceutical companies, the number of shares sold short in Alexion Pharmaceuticals ...
  32. Alexion, Pharmacyclics Buck Trend in Biotech Short Interest (ALXN, ...

    September 14, 2013
    Declining short interest in Alexion Pharmaceuticals (NASDAQ: PCYC) bucked the trend among leading biotech and emerging pharmaceutical ...
  33. Vertex Building A Fortress In Cystic Fibrosis

    August 28, 2013
    Vertex is in the early days of what could be a $10B franchise in cystic fibrosis treatment.
  34. Wall Street Happy To Hum La AbbVie En Rose

    July 26, 2013
    AbbVie's pipeline is better than some think, but valuation is no particular bargain right now.
  35. Short Interest in Biogen Idec and Vertex Shrinks (BIIB, CELG, ...

    June 26, 2013
    Among biotech and emerging pharmaceutical companies, Celgene (NASDAQ: CELG) and saw the most significant rise in short interest ...
  36. Roche, Reloaded

    May 21, 2013
    Roche has one of the best long-term growth profiles in the Big Pharma space
  37. Amgen Chased By The Bubble

    May 8, 2013
    Amgen really needs the pipeline to come through to support this valuation.
  38. The Smart Money Loves These 10 Stocks

    January 14, 2013
    During the past 10 years, the best hedge funds have consistently produced market-beating returns, driving huge capital inflows ...
  39. Healthcare Stocks, Including Gilead, Making Big Moves on October ...

    October 24, 2012
    So far today, the Nasdaq remains relatively unchanged, the S&P 500 has risen 0.1% and the Dow has climbed 0.3%. The healthcare ...
  40. 15 Biotech Companies Waiting For FDA Approval

    March 21, 2012
    Despite all of these uncertainties, investors still heavily focus on whether a company's new drug will be approved by the ...
  41. Hanesbrands Still A Good Fit

    February 21, 2012
    The long-term appeal of Hanesbrands' business is still there, provided management delivers on its promise to reduce debt.
  42. Playing A Biotech Breakout

    February 15, 2012
    Strong pipelines for the biotech sector as well as a wave of merger activity, have investors flocking to the stocks.
  43. Big Bets on High-Flying Pharma Stock

    February 9, 2012
    Following bullish earnings, Karee Venema of Schaeffer’s Research writes that call buyers are piling in to one biopharmaceutical ...
  44. 2011's Biggest Mergers and Acquisitions

    December 30, 2011
    M&A activity rebounded in a big way in 2011. Here's a look back at the biggest mergers and acquisitions during the year.
  45. Is Third Time The Charm For Gilead?

    November 22, 2011
    Gilead is going all in on Hep C, as it acquires Pharmasset in a massive deal.
  46. A Deal At Last For Sanofi And Genzyme

    February 18, 2011
    Though Sanofi finally got its way in acquiring Genzyme, time will determine if stockholders will truly benefit.
  47. InterMune - The Black Knight Of Biotech?

    December 21, 2010
    Possible European approval could save the day for this risky biotech.
  48. 4 Cheap, High-Quality Stocks

    September 23, 2010
    Stocks trading below the S&P 500 P/E average are cheap, but are they a good buy?
  49. Bristol-Myers Pays A Premium For Its Partner

    September 10, 2010
    Bristol-Myers is paying a lot, but a successful HCV franchise could be worth much more.
  50. 5 Stocks Hitting Bottom

    July 29, 2010
    Making bets on stocks that have been driven down too far can be a great way to catch some of the next batch of winners.
  51. Getting In On Growth At A Great Price

    July 5, 2010
    Here are some growth-oriented stocks with below-market average P/Es that investors can pick up during this shaky market to ...
  52. There Is Life After Death, At Least In Biotech

    June 22, 2010
    Clinical failure is not the end of the story for all biotechs. How do some survive while others disappear?
  53. Biotech Bargains

    June 17, 2010
    High-growth biotech stocks are now priced like value plays.
  54. FDA Makes InterMune Sick

    May 10, 2010
    Should investors hang on despite a devastating FDA decision?
  55. 5 Stocks From McDonald's Portfolio

    April 27, 2010
    Take a look inside the profit sharing and savings portfolio McDonald's runs for its employees.
  56. Stocks That Institutional Investors Love

    February 4, 2010
    Looking at the stocks that institutional investors own can provide a good starting point for the everyday investor.
  57. Earnings Winners You Shouldn't Miss

    January 29, 2010
    Plenty of companies have posted disappointing results for last quarter, but a few off-the-radar names have done surprisingly ...
  58. The Best Performing Stocks Of The Decade

    June 9, 2009
    Investors who were able to see past the losses and volatility that some of these companies had in the beginning were amply ...
  59. Is Now The Time To Buy Pharmaceuticals?

    May 5, 2009
    Despite the recession, the pharmaceutical sector continues to show strong year-over-year earnings results and demand worldwide.
  60. Money Flowing Into Biotech Stocks

    January 12, 2009
    Institutions have their eyes on biotech stocks. Does this sector have your attention?
  61. Biotech ETFs Under The Microscope

    July 24, 2008
    Biotech ETFs have been immune to the falling stock market. We examine three top performing funds to find a surprising long-term ...
  62. Getting Technical With Biotech

    July 11, 2008
    Watch as a blend of technical and fundamental analysis reveals hidden gems in this unpredictable sector.
  63. Gilead Is A Winner (GILD)

    June 15, 2007
    With its successful product pipeline, Gilead shines among biotechs, and its future is only getting brighter.
Trading Center